Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Further cash for GSK shareholders as Aspen fronts £164 million for RoW OTC products

This article was originally published in Scrip

Executive Summary

South African company Aspen has agreed to acquire a basket of over-the-counter products from GlaxoSmithKline for R2.1 billion (£164 million), for markets outside Europe and North America. The products, which include Phillips Milk of Magnesia, the pain relief brand Solpadeine, the low-dose aspirin Cartia, the antiseptic brand Dequadin and the antacid Zantac (ranitidine), generated sales in the territories concerned of about £60 million last year.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts